AbbVie: Back on Growth Path After Humira – New Billion-Dollar Potentials and P/E 16.4

AbbVie is a leading biopharmaceutical company and is increasingly offsetting the decline of Humira with new growth drivers in immunology, neurology, and oncology. Skyrizi and Rinvoq are growing at more than 24% and are the company's main growth engines. With FDA approval for JUVMO, the acquisition of Apogee, and strong oncology data, AbbVie is expanding its next phase of growth. The stock of AbbVie (ABBV) continues its long-term upward trend and has gained about 16.5% since the beginning of the year. On September 23, a new all-time high...